FDA grants Fast Track designation to prostate cancer treatment
Drug Discovery World
JULY 8, 2024
Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Reece Armstrong, Editor, DDW The post FDA grants Fast Track designation to prostate cancer treatment appeared first on Drug Discovery World (DDW).
Let's personalize your content